Pacific Biosciences Of California (PACB) Cash & Equivalents Growth (1y) (2011 - 2026)
Pacific Biosciences Of California (PACB) Cash & Equivalents Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 154.42 Bn | 147.76 Bn | 6.27 Bn | 4.15% |
| 2 | Stryker | 118.12 Bn | 115.25 Bn | 3.81 Bn | 24.05% |
| 3 | Medtronic | 101.72 Bn | 93.55 Bn | 5.76 Bn | -7.50% |
| 4 | Boston Scientific | 67.19 Bn | 65.98 Bn | 3.61 Bn | 100.41% |
| 5 | Edwards Lifesciences | 50.69 Bn | 47.02 Bn | 1.29 Bn | -22.13% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 20.15% |
| 7 | Dexcom | 28.09 Bn | 26.97 Bn | 750.30 Mn | 23.57% |
| 8 | GE HealthCare Technologies | 28.08 Bn | 26.02 Bn | 1.98 Bn | -7.71% |
| 9 | Steris | 19.80 Bn | 19.37 Bn | 697.10 Mn | 156.03% |
| 10 | Pacific Biosciences Of California | 426.62 Mn | 150.66 Mn | 12.84 Mn | -3.82% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.82% |
| Dec 31, 2025 | 15.06% |
| Sep 30, 2025 | -27.59% |
| Jun 30, 2025 | -44.94% |
| Mar 31, 2025 | -23.67% |
| Dec 31, 2024 | -69.22% |
| Sep 30, 2024 | -79.78% |
| Jun 30, 2024 | -52.45% |
| Mar 31, 2024 | -78.34% |
| Dec 31, 2023 | -44.66% |
| Sep 30, 2023 | 26.68% |
| Jun 30, 2023 | -32.58% |
| Mar 31, 2023 | -17.44% |
| Dec 31, 2022 | -29.44% |
| Jun 30, 2022 | -32.48% |
| Mar 31, 2022 | -54.04% |
| Dec 31, 2021 | 464.54% |
| Jun 30, 2021 | 960.85% |
| Mar 31, 2021 | 1,254.01% |
| Dec 31, 2020 | 175.46% |